Abstract:Asthma is a chronic inflammatory disease of the airway that is characterized by cellular infiltration and activation. These processes are induced by overexpression of chemokines and cytokines, such as eotaxin, IL-1beta and GM-CSF. These mediators are downstream targets for the transcription factors activator protein-1 (AP-1) and nuclear factor-kappaB (NF-kappaB), which control the expression of most immunomodulatory genes and whose activity and expression are elevated in asthma. Glucocorticoids are the most effective anti-inflammatory drugs used in the treatment of chronic inflammatory diseases such as asthma. They act by binding to a specific glucocorticoid receptor (GR) that on activation translocates to the nucleus and either increases (transactivates) or decreases (transrepresses) the expression of responsive genes. Transrepression is the major mechanism of glucocorticoid action in inhibiting inflammatory gene expression. Thus, the ability of the transcription factors AP-1 and NF-kappaB to induce gene transcription is attenuated by GR. Although only 5-10% of asthmatic subjects are glucocorticoid-insensitive, these subjects account for over 50% of the health-care costs for asthma (> $6 billion per annum). Examining these patients also gives an insight into important aspects of glucocorticoid action in controlling inflammation and into the development of potential new drugs. Biochemical and genomic studies have indicated abnormal induction of the c-Jun N-terminal kinase (JNK) pathway in some of these patients. The ability of most patients to respond to dexamethasone with induction of histone acetylation correlated with nuclear translocation of GR. However, a subgroup of these patients had an inability to correctly interact with the basal transcription complex in spite of high levels of nuclear GR. This suggests that cross-talk between pro- and anti-inflammatory transcription factors may modulate activation of the transcriptional complex and thereby reduce steroid actions.

Annexin A1 and glucocorticoids as effectors of the resolution of inflammation

Annexin A1 and the Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and Clearance

Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis

Annexin 1: more than an anti-phospholipase protein

Regulation of skin inflammation and T cell activity by annexin A1 (114.3)

Annexin A1 Exerts Renoprotective Effects in Experimental Crescentic Glomerulonephritis

Annexin A1: Uncovering the Many Talents of an Old Protein

Annexin A2 in Inflammation and Host Defense

Functional and ultrastructural analysis of annexin A1 and its receptor in extravasating neutrophils during acute inflammation

Anti-inflammatory drugs, eicosanoids and the annexin A1/FPR2 anti-inflammatory system

Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms

Annexin A1 Is a Physiological Modulator of Neutrophil Maturation and Recirculation Acting on the CXCR4/CXCL12 Pathway

Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury.

Annexin A1 regulates intestinal mucosal injury, inflammation, and repair

New Insights into the Anti-inflammatory Mechanisms of Glucocorticoids: An Emerging Role for Glucocorticoid-Receptor-Mediated Transactivation

Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling

Therapeutic Potential of Annexin A1 Modulation in Kidney and Cardiovascular Disorders

Cross‐talk between pro‐inflammatory transcription factors and glucocorticoids

Molecular mechanisms of glucocorticoid action in mast cells

Effects of Endogenous Glucocorticoids on Allergic Inflammation and TH1/TH2 Balance in Airway Allergic Disease

Glucocorticoids regulate lipid mediator networks by reciprocal modulation of 15-lipoxygenase isoforms affecting inflammation resolution